These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1285687)

  • 1. [Mechanism of action of antilipemic drugs].
    Bruckert E; Turpin G
    Arch Mal Coeur Vaiss; 1992 Sep; 85 Spec No 2():109-12. PubMed ID: 1285687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia and atherosclerosis. A forecast of pharmaceutical approaches.
    Gotto AM
    Circulation; 1993 Apr; 87(4 Suppl):III54-9. PubMed ID: 8462181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biochemical and experimental aspects of the lipid-lowering drugs pharmacology (author's transl)].
    Jacotot B
    Pathol Biol (Paris); 1979 May; 27(5):305-13. PubMed ID: 388303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biochemical and experimental aspects of the lipid-lowering drugs pharmacology (author's transl)].
    Jacotot B
    Sem Hop; 1979 Dec 8-15; 55(41-42):1947-55. PubMed ID: 231322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipids for psychiatrists - an overview.
    Young IS
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):66-75. PubMed ID: 16280339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination of potentially atherogenic triglyceride-rich lipoprotein particles].
    Alaupovic P; Blankenhorn DH
    Klin Wochenschr; 1990; 68 Suppl 22():38-42. PubMed ID: 2087077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular mechanism of action of the fibrates].
    Fruchart JC; Duriez P; Staels B
    J Soc Biol; 1999; 193(1):67-75. PubMed ID: 10851558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 2,3-dihydrophthalazine-1,4-dione on Sprague Dawley rats lipid metabolism and serum lipoproteins.
    Hall IH; Wong OT; Reynolds DJ; Oswald CB
    Biomed Biochim Acta; 1988; 47(4-5):423-33. PubMed ID: 3240293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of rutin on lipids, lipoproteins, lipid metabolizing enzymes and glycoproteins in streptozotocin-induced diabetic rats.
    Stanely Mainzen Prince P; Kannan NK
    J Pharm Pharmacol; 2006 Oct; 58(10):1373-83. PubMed ID: 17034661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipid transport in blood from the protein chemistry viewpoint].
    Titov VN
    Vopr Pitan; 1995; (2):9-13. PubMed ID: 7483472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The possible means for the pharmacological correction of lipid metabolic disorders in atherosclerosis].
    Piskun RP; Pentiuk AA; Serkova VK; Polesia TL; Savitskaia EA
    Eksp Klin Farmakol; 1997; 60(2):78-85. PubMed ID: 9206580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
    Visnegarwala F; Maldonado M; Sajja P; Minihan JL; Rodriguez-Barradas MC; Ong O; Lahart CJ; Hasan MQ; Balasubramanyam A; White AC
    J Infect; 2004 Nov; 49(4):283-90. PubMed ID: 15474625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J
    Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering agents and their meaning in the treatment of the fat metabolism-atherosclerosis functional circle.
    Kuemmerle HP
    Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):289-96. PubMed ID: 7263106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal lipid metabolism, familial hyperlipidaemia, lipid intervention and their benefits.
    Koner BC; Goswami K; Kavitha S; Moorthy RS
    J Indian Med Assoc; 2003 Feb; 101(2):89-92. PubMed ID: 12841490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of pirozadil on plasma lipids and lipoproteins in 1185 hyperlipidaemic subjects. Multicentre study in general practice in Spain.
    Tapounet R; Marti Ragué I
    Drugs Exp Clin Res; 1987; 13(7):447-50. PubMed ID: 3652931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanism of action of hypolipemic drugs].
    Fruchart JC
    J Pharm Belg; 1992; 47(4):345-50. PubMed ID: 1403601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.